European Journal of Haematology

Papers
(The H4-Index of European Journal of Haematology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect97
59
51
Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma49
Issue Information47
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes44
Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia35
Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia34
Augmenter of liver regeneration promotes drug resistance of acute lymphoblastic leukemia through the alteration of mitochondrial functions and the inhibition of the mitochondrial apoptosis pathway28
Myeloproliferative Neoplasms and Dementia Risk: A Population‐Based Cohort Study28
Vaccination in Multiple Myeloma: Challenges and Strategies27
The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review26
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk underg26
Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma25
Flow cytometry for comprehensive assessment of platelet functional activity in response to ADP stimulation25
Issue Information23
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)‐T cell therapy in patients with hematological malignancy23
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma20
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial19
Long‐term effectiveness of eculizumab: Data from the International PNH Registry19
Impact of Gut Microbiota and Inflammatory Cytokines on Immune Thrombocytopenia19
0.096964836120605